Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AIM ImmunoTech Inc. Director's Dealing 2011

Sep 26, 2011

35334_dirs_2011-09-26_97c79bcb-4722-47db-82bc-6f16b16bb618.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2011-09-23

Reporting Person: Cavalli Ralph Christopher (VP, Quality Control)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2011-09-23 Options to buy Common Stock $0.37 J 40000 Acquired 2021-09-15 Common Stock (40000) Direct

Footnotes

F1: Options acquired as a result of employment agreement.